Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Eucrisa (crisaborole) is indicated for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 3 months of age and older.
• This summary is based on the review of six systematic review(s)/meta-analysis(es). ^[1-7]
• Pimecrolimus vs. Vehicle (Children): Pimecrolimus demonstrated higher efficacy in achieving an Investigator's Global Assessment (IGA) score of 0/1 up to week 6 compared to the vehicle in children with atopic dermatitis (AD).
• Crisaborole vs. Other Topical Treatments: Crisaborole showed superior efficacy over the vehicle in achieving Investigator’s Static Global Assessment (ISGA) 0/1 and a significant reduction in target lesion scores. It was also found to be comparable to tacrolimus and more effective than pimecrolimus in certain measures.
• Effectiveness in Pediatric Population: Tacrolimus, pimecrolimus, and crisaborole were effective in managing pediatric AD, with crisaborole demonstrating significant benefits in reducing AD severity and maintaining improvements across multiple outcomes.
• Pimecrolimus and tacrolimus had similar safety profiles, with no significant differences in adverse events noted in children and mixed populations. Common adverse events included burning sensation, pruritus, and cutaneous infections, with no significant increased risk of malignancy associated with topical calcineurin inhibitors.
• Crisaborole and PDE4 inhibitors were generally well tolerated with no significant differences in treatment-emergent or serious adverse events compared to the vehicle. Pain at the application site was a notable adverse effect for PDE4 inhibitors.
• There is no population or subgroup information available in the reviewed studies.